Glycine receptor autoantibodies disrupt inhibitory neurotransmission.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 11 2019
Historique:
received: 01 02 2019
revised: 25 07 2019
accepted: 07 08 2019
pubmed: 9 10 2019
medline: 27 5 2020
entrez: 9 10 2019
Statut: ppublish

Résumé

Chloride-permeable glycine receptors have an important role in fast inhibitory neurotransmission in the spinal cord and brainstem. Human immunoglobulin G (IgG) autoantibodies to glycine receptors are found in a substantial proportion of patients with progressive encephalomyelitis with rigidity and myoclonus, and less frequently in other variants of stiff person syndrome. Demonstrating a pathogenic role of glycine receptor autoantibodies would help justify the use of immunomodulatory therapies and provide insight into the mechanisms involved. Here, purified IgGs from four patients with progressive encephalomyelitis with rigidity and myoclonus or stiff person syndrome, and glycine receptor autoantibodies, were observed to disrupt profoundly glycinergic neurotransmission. In whole-cell patch clamp recordings from cultured rat spinal motor neurons, glycinergic synaptic currents were almost completely abolished following incubation in patient IgGs. Most human autoantibodies targeting other CNS neurotransmitter receptors, such as N-methyl-d-aspartate (NMDA) receptors, affect whole cell currents only after several hours incubation and this effect has been shown to be the result of antibody-mediated crosslinking and internalization of receptors. By contrast, we observed substantial reductions in glycinergic currents with all four patient IgG preparations with 15 min of exposure to patient IgGs. Moreover, monovalent Fab fragments generated from the purified IgG of three of four patients also profoundly reduced glycinergic currents compared with control Fab-IgG. We conclude that human glycine receptor autoantibodies disrupt glycinergic neurotransmission, and also suggest that the pathogenic mechanisms include direct antagonistic actions on glycine receptors.

Identifiants

pubmed: 31591639
pii: 5583666
doi: 10.1093/brain/awz297
pmc: PMC6821286
doi:

Substances chimiques

Autoantibodies 0
Immunoglobulin Fab Fragments 0
Immunoglobulin G 0
Receptors, Glycine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3398-3410

Subventions

Organisme : Medical Research Council
ID : G0801316
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0900613
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L01095X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400136
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0600368
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400627
Pays : United Kingdom
Organisme : Medical Research Council
ID : G116/147
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0601440
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209807/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212285/Z/18/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9805989
Pays : United Kingdom

Informations de copyright

© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.

Références

J Neurol Sci. 2013 Dec 15;335(1-2):221-3
pubmed: 24045088
Ann Neurol. 2015 Mar;77(3):381-98
pubmed: 25369168
Mol Brain. 2014 Jan 09;7:2
pubmed: 24405574
Brain. 2014 Aug;137(Pt 8):2178-92
pubmed: 24951641
Nat Neurosci. 2014 Feb;17(2):232-9
pubmed: 24390226
Neuropharmacology. 2009 Jan;56(1):303-9
pubmed: 18721822
Neuron. 2008 Mar 27;57(6):819-26
pubmed: 18367083
Epilepsia. 2014 Mar;55(3):414-22
pubmed: 24502404
Nat Genet. 2006 Jul;38(7):801-6
pubmed: 16751771
J Neurol Neurosurg Psychiatry. 1998 Nov;65(5):633-40
pubmed: 9810930
J Neurol Neurosurg Psychiatry. 1980 Sep;43(9):836-42
pubmed: 6252294
Mol Cell Neurosci. 2002 Feb;19(2):201-15
pubmed: 11860273
EMBO J. 1994 Sep 15;13(18):4223-8
pubmed: 7925268
Nat Rev Neurosci. 2016 Feb;17(2):103-17
pubmed: 26806629
Brain. 2015 Jan;138(Pt 1):94-109
pubmed: 25392198
Brain. 2018 Nov 1;141(11):3144-3159
pubmed: 30346486
Cold Spring Harb Protoc. 2013 Apr 01;2013(4):319-26
pubmed: 23547162
JAMA Neurol. 2016 Jun 1;73(6):714-20
pubmed: 27065452
Physiol Rev. 2017 Apr;97(2):839-887
pubmed: 28298428
Curr Opin Neurol. 2017 Jun;30(3):310-316
pubmed: 28306573
Mov Disord. 2002 Sep;17(5):853-66
pubmed: 12360534
J Physiol. 2003 Jul 15;550(Pt 2):373-83
pubmed: 12754315
Neurol Neuroimmunol Neuroinflamm. 2014 Jul 03;1(2):e16
pubmed: 25340068
J Biol Chem. 2012 Aug 17;287(34):28975-85
pubmed: 22700964
Nature. 2001 May 31;411(6837):587-90
pubmed: 11385573
N Engl J Med. 1978 May 18;298(20):1116-22
pubmed: 643030
Brain Res. 2000 Apr 7;861(1):45-58
pubmed: 10751564
Nat Genet. 1993 Dec;5(4):351-8
pubmed: 8298642
Epilepsia Open. 2017 Jul 19;2(3):355-359
pubmed: 29588966
Neuron. 1989 Sep;3(3):339-48
pubmed: 2561971
JAMA Neurol. 2015 Feb;72(2):187-93
pubmed: 25506781
J Neurosci. 2010 Apr 28;30(17):5866-75
pubmed: 20427647
Proc Natl Acad Sci U S A. 1977 Jul;74(7):3090-4
pubmed: 268657
Neurology. 2008 Oct 14;71(16):1291-2
pubmed: 18852446
Neuron. 2018 Oct 10;100(1):91-105.e9
pubmed: 30146304
Epilepsia. 2013 Jun;54(6):1028-35
pubmed: 23464826
Pract Neurol. 2014 Apr;14(2):123-7
pubmed: 23564494
Neurol Neuroimmunol Neuroinflamm. 2017 Jul 18;4(5):e386
pubmed: 28761905
Neuron. 1998 Nov;21(5):1067-78
pubmed: 9856462
Arch Neurol. 2012 Feb;69(2):230-8
pubmed: 22332190
J Clin Invest. 1996 Nov 15;98(10):2358-63
pubmed: 8941654

Auteurs

Sarah J Crisp (SJ)

UCL Institute of Neurology, University College London, London, UK.

Christine L Dixon (CL)

UCL Institute of Neurology, University College London, London, UK.

Leslie Jacobson (L)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Elodie Chabrol (E)

UCL Institute of Neurology, University College London, London, UK.

Sarosh R Irani (SR)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

M Isabel Leite (MI)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Guy Leschziner (G)

Department of Neurology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Department of Clinical Neuroscience, King's College London, London, UK.

Sean J Slaght (SJ)

Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Angela Vincent (A)

UCL Institute of Neurology, University College London, London, UK.
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Dimitri M Kullmann (DM)

UCL Institute of Neurology, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH